Provisions for Drug Advertisement Examination

作者:法律资料网 时间:2024-07-03 20:57:26   浏览:9690   来源:法律资料网
下载地址: 点击此处下载

Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


下载地址: 点击此处下载

中共中央宣传部办公厅、教育部办公厅关于进一步加强中小学时事教育的意见

中共中央宣传部办公厅 教育部办公厅


中共中央宣传部办公厅、教育部办公厅关于进一步加强中小学时事教育的意见

教基一厅〔2012〕4号


各省、自治区、直辖市党委宣传部、教育厅(教委),新疆生产建设兵团党委宣传部、教育局:
  为贯彻落实党的十七届六中全会精神,将社会主义核心价值体系融入中小学教育全过程,发挥时事教育对促进中小学生健康成长的重要作用,提高中小学时事教育的吸引力和感染力,现就加强中小学时事教育提出以下意见。
  一、充分认识加强中小学时事教育的重要性和紧迫性
  开展以当前国内外形势、党和国家的重大方针政策及社会热点问题为主要内容的时事教育,是未成年人思想道德建设的重要组成部分,是中小学德育工作的重要方面,是推进素质教育的重要内容,必须适应时代发展的要求予以加强,必须遵循中小学生的成长规律和教育规律不断创新。
  开展时事教育,对于中小学生了解国情世情,了解我国改革开放和社会主义现代化取得的成就和进程,感受到共产党好、社会主义好、改革开放好、伟大祖国好、各族人民好,更客观更全面更深入地认识周围事物和世界,坚定对中国特色社会主义的信心和信念,形成正确的世界观、人生观和价值观,增强社会责任感和使命感,培养胸怀祖国、放眼世界的中国特色社会主义事业合格建设者和可靠接班人,具有重要意义。
  当代中小学生成长在一个大发展大变革的时代,越来越关心国家发生的事、世界发生的事。由于信息传播速度更加迅捷、传播渠道更加多样、传播范围更加广泛,他们获得的信息也越来越多、越来越快。引导广大中小学生深入了解发生的重大事件本质,作出正确的价值判断,十分重要和紧迫。
  二、采取有力措施切实加强中小学时事教育
  各地要从实际出发,采取有效措施,增强中小学时事教育的实效。
  1.加强资源开发建设。各地宣传、教育等部门和中小学要用好国家主流媒体的新闻报道,结合本地本校学生的实际开发时事资源,满足开展时事教育的需要。中宣部和教育部将根据中央关于贯彻十七届六中全会开展形势政策教育的部署,指导做好时事教育资源的开发。在继续指导编辑使用好《时事报告(中学生版)》基础上,编写《时事报告(小学生版)》。指导编辑出版《时事课堂》等音像期刊,供学校开展时事教育教学使用。
  2.加强师资队伍建设。各地教育部门要加强对校长、教师的形势政策和国情教育,在组织校长、德育课程教师和班主任培训时,要安排时事教育的内容,提高他们开展时事教育的意识和能力。教育部将在校长、德育课程教师和班主任国家级培训中,安排时事教育的内容。
  3.改进教育方式方法。要根据不同学段学生年龄特点,采取学生喜闻乐见、富有启发的方式进行时事教育,多采取音像等更加直观、生动、形象的呈现方式,还可组织学生到档案馆、博物馆、纪念馆等场所现场教学,提高时事教育活动的吸引力和实效性。
  4.落实时间和经费保障。各地各校要充分利用德育课、晨会、班团队会、综合实践活动等时间,以及其他开展集体教育活动时间,对学生进行时事教育。要提供必要的经费,确保时事教育活动的顺利开展。
  三、加强对中小学时事教育工作的组织领导
  1.加强领导。各地教育部门要在当地党委宣传部门的指导下,根据全国形势政策宣传教育工作的部署,结合当地实际,精心安排好学校的时事教育工作。中小学要将时事教育纳入教育教学计划,有人负责,有实施办法。
  2.加强协作。各地教育、宣传部门要主动联系文明办、关工委,密切配合,为中小学开展时事教育提供物质资源和人力保障。倡导邀请地方党政领导为学生做形势报告,鼓励“五老”人员及其他有专业背景的志愿者,为学校开展时事教育提供帮助。
  3.加强督导。各级教育督导部门要加强对中小学开展时事教育的督导检查,形成制度。要将中小学开展时事教育教学工作情况作为督导评估学校工作的重要内容,纳入教育部门对中小学德育工作年度考核的指标体系。学校要把时事教育开展情况作为评价德育课程教师和德育干部的重要指标。


                    中共中央宣传部办公厅 教育部办公厅

                       二○一二年二月二十三日











拉萨市林地管理办法

西藏自治区拉萨市人民政府


政府令第29号

拉萨市林地管理办法


  《拉萨市林地管理办法》已经2010年11月15日拉萨市人民政府第13次常务会议审议通过,现予发布,自2011年1月1日起施行。

  市长:多吉次珠
二O一O年十一月十七日

拉萨市林地管理办法

  第一条为加强林地的保护和管理,合理利用林地,根据《中华人民共和国森林法》、《中华人民共和国森林法实施条例》、《西藏自治区林地管理办法》及有关法律、法规,结合本市实际,制定本办法。

  第二条本办法所称林地,包括郁闭度0.2以上的乔木林地以及灌木林地、疏林地、采伐迹地、火烧迹地、未成林造林地、苗圃地和县级以上人民政府规划的宜林地。

  第三条本办法适用于本市行政区域范围内林地的保护和管理工作。

  第四条依法实行林地登记发证制度、林地用途管制制度。市、县(区)人民政府应当加强林地管理,制止侵占和滥用林地的违法行为。

  第五条市林业绿化行政主管部门负责本市林地的管理和监督工作。

  市住房和城乡建设、发展和改革、国土资源规划、环境保护、水利、交通运输、农牧、财政、公安、民政等有关部门,应当按照各自职责协助林业绿化行政主管部门做好林地的保护和管理工作。

  第六条林地属于国家所有或者集体所有,在明晰产权,保持集体林地所有权不变的前提下,林地承包经营权和林木所有权应当落实到户,确立农民的经营主体地位。

  第七条林地的所有者或者使用者应当依照相关规定向市林业绿化行政主管部门提出权属登记申请,由市人民政府登记造册,核发权属证书,确认林地的所有权或者使用权。

  第八条申请林地权属初始登记,应当提交下列材料:(一)林地权属登记申请表;(二)申请人身份证明或者资格证明;(三)林地权属证明材料;(四)法律、法规规定的其他材料。

  第九条本办法所称林地使用分为下列三类:(一)征收、占用林地是指因建设工程需要,改变林地性质,将林地转为建设用地;(二)临时占用林地是指不改变林地性质,占用林地进行勘测、修筑设施、采石、采矿、取沙等活动,占用期限不得超过2年。占用期间不得修筑永久性建筑物,期满后必须恢复林业生产条件;(三)林业生产占用林地是指森林经营单位在所经营的林地范围内修筑直接为林业生产服务的工程设施,需要占用林地。

  第十条勘查、开采矿藏和修建公路、水利、电力、通讯等工程,需要占用或者征收林地的,申请人应当向林业绿化行政主管部门提出申请,经林业绿化行政主管部门审核同意后,方可办理建设用地审批手续。未经林业绿化行政法主管部门审核同意的,国土资源规划行政主管部门不得办理相关手续。

  第十一条征收、占用林地的单位或者个人,应当向林地所在地林业绿化行政主管部门提交下列材料:(一)征收、占用林地申请报告;(二)申请人是单位的,提供单位证明和法定代表人身份证明;是个人的提供身份证明;(三)被征收或者占用林地的权属证明材料;(四)建设项目立项批准文件;(五)征收、占用林地可行性研究报告和现场勘查报告;(六)与被征收、占用林地的所有权人达成的林地、林木补偿费和安置补助费协议或者证明;(七)法律、法规规定的其他材料。

  第十二条林业绿化行政主管 部门应当自受理申请之日起5个工作日内审查完毕。经审查,符合法律、法规和本办法规定的,应当予以受理;需补正材料的,应当一次性告知申请人补正;作出不予批准决定的,应当书面说明理由并告知申请人。

  第十三条临时占用林地的,按照下列批准权限办理审批手续:(一)临时占用除防护林和特种用途林以外的其他林地面积2公顷以上10公顷以下的,由市林业绿化行政主管部门审批;(二)临时占用除防护林和特种用途林以外的其他林地面积2公顷以下的,由县(区)林业绿化行政主管部门审批。

  第十四条林业绿化行政主管部门经审核同意申请人征收、占用或者临时占用林地的,自受理申请之日起10个工作日内,应当书面通知申请人预缴森林植被恢复费。

  第十五条建设项目应当根据总体设计一次性申请征收、占用林地,不得分割申请。分期建设项目,应当分期申请和审批,不得先征待用或者未批先用。

  第十六条经批准使用的建设项目需要采伐林木的,建设工程用地单位应当依法向林木所在地的林业绿化行政主管部门申领林木采伐许可证,并纳入当年采伐限额。

  第十七条经依法批准,临时占用林地的单位和个人在从事生产 经营活动中,应当采取有效措施保护林地,防止水土流失,不得改变林地用途。

  第十八条严格林地用途管制制度。禁止下列破坏林地的行为:(一)擅自将林地改变为非林地;(二)擅自在林地上进行采石、采矿、取土、取沙、建房、修筑工程等活动;(三)擅自开垦林地种植农作物。坡度二十五度以上的山地已开垦种植农作物的,应当依法限期退耕还林。确需改变林地性质和用途的,必须依法办理相关审批手续。

  第十九条征收、占用林地的单位或个人,应当按规定向林业绿化行政主管部门缴纳森林植被恢复费,并向被征收、占用的单位或个人支付林地补偿费、林木及其他地上附着物补偿费、安置补助费。

  临时占用林地的单位或个人,应当按规定缴纳森林植被恢复费,并向被占用的单位或个人支付林木及其他地上附着物补偿费。

  小城镇建设、农牧民安居工程、乡村公路建设征收、占用或者临时占用林地的,免缴森林植被恢复费,国家另有规定的除外。

  第二十条林地补偿费,按照其被征收、占用前3年当地耕地平均年产值的3至6倍补偿。

  第二十一条林木及其他地上附着物补偿费标准按照自治区有关 规定执行。

  第二十二条安置补助费标准按征地前三年平均产值的3倍补

  偿。

  第二十三条森林植被恢复费标准按照国家有关规定执行。

  第二十四条森林植被恢复费应当实行专款专用,专项用于植树造林、恢复森林植被,包括森林资源调查、规划设计、整地、造林、抚育、护林防火、病虫害防治、资源管护等支出,不得平调、截留或挪作他用。

  第二十五条擅自改变林地用途的,由市林业绿化行政主管部门责令限期恢复原状,并处以非法改变用途林地每平方米10元至30元的罚款。

  第二十六条林业绿化行政主管部门工作人员以及有关部门工作人员有下列情形之一的,对主要负责人和责任人员,依法给予行政处分;涉嫌犯罪的,移交司法机关处理。

  (一)不依法办理林地权属登记或者登记不当而不纠正的;(二)擅自改变林地类别和性质的;

  (三)弄虚作假审批林地使用的;

  (四)超越法定权限、程序和期限审批林地使用的;(五)对林地违法行为依法应当给予行政处罚而不予处罚或者行政处罚显失公正的;(六)其他玩忽职守、滥用职权、徇私舞弊的行为。

  第二十七条本办法自2011年1月1日起施行。